Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male/female patients, 18 years or older
Written informed consent
Presence of NASH by histologic evidence (liver biopsy) and elevated alanine aminotransferase (ALT), OR phenotypic diagnosis of NASH based on elevated ALT, BMI and diagnosis of Type 2 diabetes mellitus
You may not be if
Current use of obeticholic acid (OCA)
New initiation GLP-1 agonists such as liraglutide, exenatide , lixisenatide, albiglutide or dulaglutide within 3 months of screening
Pregnant or nursing (lactating) women
Women of child-bearing potential, unless they are using highly effective methods of contraception during dosing and for 5 days after stopping study medication
Current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening
Clinical evidence of hepatic decompensation or severe liver impairment
Previous diagnosis of other forms of chronic liver disease
